I'm LongbridgeAI, I can summarize articles.Jilin Province Huinan Changlong Bio-Pharmacy reported FY26 H1 profit attributable to shareholders of RMB 122.84 million, a 19.25% increase year-on-year, despite a slight 0.87% revenue decline to RMB 435.05 million. Operating profit rose to RMB 151.77 million, driven by an expanded gross margin of 83.9% due to lower costs. The company maintains a zero gearing ratio with RMB 234.22 million in cash. Operational upgrades included automation enhancements and the commercial launch of the oral liquid workshop following GMP inspection.
- Jilin Province Huinan Changlong Bio-Pharmacy posted profit attributable to shareholders of RMB 122.84 million, up 19.25% year-on-year. * Turnover edged down 0.1% to RMB 435.05 million, while profit from operations climbed to RMB 151.77 million. * Gross margin widened to 83.9%, attributed to lower production and material costs. * Gearing ratio was about 0% with no short-term bank borrowings; cash and cash equivalents rose to RMB 234.22 million. * Upgrades added automation across solid-dose and packaging lines; the oral liquid workshop entered commercial operation following an August 2025 GMP inspection. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jilin Province Huinan Changlong Bio-Pharmacy Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12285711), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)